Current Controlled Trials in Cardiovascular Medicine最新文献

{"title":"Combining short stent implantation and drug-eluting stenting for routine use yields a low restenosis rate.","authors":"Ulrich Dietz,&nbsp;Cheryl Dauer,&nbsp;Heinz Lambertz","doi":"10.1186/1468-6708-6-18","DOIUrl":"https://doi.org/10.1186/1468-6708-6-18","url":null,"abstract":"<p><strong>Background: </strong>Stent length serves as a predictor of restenosis in use of bare metal stents (BMS). This has been demonstrated in a feasibility study that used a single short BMS implant (<9 mm) in a high proportion of lesions; the study observed a low rate of restenosis.</p><p><strong>Methods: </strong>We performed a pilot prospective study to investigate in a series of consecutive patients the immediate and long-term effects of implantation of either 1) a single short BMS for all lesions with low probability of restenosis or 2) a drug-eluting stent (DES) for all other lesions.</p><p><strong>Results: </strong>The 200 patients studied had 236 coronary artery lesions that were treated with short BMS in 168/236 patients (71.2%) and with DES in 68/236 patients (28.8%). Angiographic success was achieved in 230/236 lesions (97.5%) and procedural success in 194/200 patients (97.0%). Restenosis occurred in 15/153 lesions (9.8%) after short BMS, in 3/62 lesions (4.8%) after DES, and in 18/215 of all lesions (8.4%) angiographically controlled after six to eight months. Target vessel revascularization was performed in 16/218 lesion (7.4%).</p><p><strong>Conclusion: </strong>Most of the coronary artery lesions in this small group of consecutive patients were treated sufficiently with a single BMS implant. This differential approach of treating suitable lesions in medium- to large-sized vessels with a single short BMS device and treating all other lesions with a DES implant resulted in a low incidence of restenosis.</p>","PeriodicalId":53230,"journal":{"name":"Current Controlled Trials in Cardiovascular Medicine","volume":"6 ","pages":"18"},"PeriodicalIF":0.0,"publicationDate":"2005-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1468-6708-6-18","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25748753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Compliance of a cobalt chromium coronary stent alloy--the COVIS trial.","authors":"Jens Hagemeister,&nbsp;Frank M Baer,&nbsp;Robert H G Schwinger,&nbsp;Hans W Höpp","doi":"10.1186/1468-6708-6-17","DOIUrl":"https://doi.org/10.1186/1468-6708-6-17","url":null,"abstract":"<p><strong>Background: </strong>Cobalt chromium coronary stents are increasingly being used in percutaneous coronary interventions. There are, however, no reliable data about the characteristics of unfolding and visibility of this stent alloy in vivo. The aim of this study is to compare cobalt chromium coronary stents with conventional stainless steel stents using intracoronary ultrasound.</p><p><strong>Methods: </strong>Twenty de novo native coronary stenoses < or = 20 mm in length (target vessel reference diameter > or = 2.5 and < or = 4.0 mm) received under sequential intracoronary ultrasound either a cobalt chromium stent (Multi-Link Vision; n = 10) or a stainless steel stent (Multi-Link Zeta; n = 10).</p><p><strong>Results: </strong>For optimal unfolding, the cobalt chromium stent requires a higher balloon deployment pressure (13.90 +/- 2.03 atm) than the stainless steel stent (11.50 +/- 2.12 atm). Furthermore, the achieved target vessel diameter of the cobalt chromium stent (Visibility-Index QCA/IVUS Multi-Link Vision 1.13 / Multi-Link Zeta 1.04) is more easily overrated by Quantitative Coronary Analysis.</p><p><strong>Conclusion: </strong>These data indicate that stent material-specific recommendations for optimal implantation pressure and different stent material with an equal design should both be considered in interpreting QCA-analysis.</p>","PeriodicalId":53230,"journal":{"name":"Current Controlled Trials in Cardiovascular Medicine","volume":"6 ","pages":"17"},"PeriodicalIF":0.0,"publicationDate":"2005-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1468-6708-6-17","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25662189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy?--A systematic review.","authors":"Madlaina Scharplatz,&nbsp;Milo A Puhan,&nbsp;Johann Steurer,&nbsp;Annalisa Perna,&nbsp;Lucas M Bachmann","doi":"10.1186/1468-6708-6-16","DOIUrl":"https://doi.org/10.1186/1468-6708-6-16","url":null,"abstract":"<p><strong>Background: </strong>Pharmacogenetic testing to individualize ACE inhibitor therapy remains controversial. We conducted a systematic review to assess the effect modification of the insertion/deletion (I/D) polymorphism of the ACE gene on any outcome in patients treated with ACE inhibitors for cardiovascular and/or renal disease.</p><p><strong>Methods: </strong>Our systematic review involved searching six electronic databases, then contacting the investigators (and pharmaceutical industry representatives) responsible for the creation of these databases. Two reviewers independently selected relevant randomized, placebo-controlled trials and abstracted from each study details on characteristics and quality.</p><p><strong>Results: </strong>Eleven studies met our inclusion criteria. Despite repeated efforts to contact authors, only four of the eleven studies provided sufficient data to quantify the effect modification by genotypes. We observed a trend towards better response to ACE inhibitors in Caucasian DD carriers compared to II carriers, in terms of blood pressure, proteinuria, glomerular filtration rate, ACE activity and progression to end-stage renal failure. Pooling of the results was inappropriate, due to heterogeneity in ethnicity, clinical domains and outcomes.</p><p><strong>Conclusion: </strong>Lack of sufficient genetic data from the reviewed studies precluded drawing any convincing conclusions. Better reporting of genetic data are needed to confirm our preliminary observations concerning better response to ACE inhibitors among Caucasian DD carriers as compared to II carriers.</p>","PeriodicalId":53230,"journal":{"name":"Current Controlled Trials in Cardiovascular Medicine","volume":"6 ","pages":"16"},"PeriodicalIF":0.0,"publicationDate":"2005-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1468-6708-6-16","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25653727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423].","authors":"Alexander Kulik,&nbsp;Michel Le May,&nbsp;George A Wells,&nbsp;Thierry G Mesana,&nbsp;Marc Ruel","doi":"10.1186/1468-6708-6-15","DOIUrl":"https://doi.org/10.1186/1468-6708-6-15","url":null,"abstract":"<p><strong>Background: </strong>Saphenous vein graft disease remains a major limitation of coronary artery bypass graft surgery. The process of saphenous vein intimal hyperplasia begins just days after surgical revascularization, setting the stage for graft atherosclerotic disease and its sequalae. Clopidogrel improves outcomes in patients with atherosclerotic disease, and is effective at reducing intimal hyperplasia in animal models of thrombosis. Therefore, the goal of this study will be to evaluate the efficacy of clopidogrel and aspirin therapy versus aspirin alone in the prevention of saphenous vein graft intimal hyperplasia following coronary artery bypass surgery.</p><p><strong>Methods: </strong>Patients undergoing multi-vessel coronary artery bypass grafting and in whom at least two saphenous vein grafts will be used are eligible for the study. Patients will be randomized to receive daily clopidogrel 75 mg or placebo, in addition to daily aspirin 162 mg, for a one year duration starting on the day of surgery (as soon as postoperative bleeding has been excluded). At the end of one year, all patients will undergo coronary angiography and intravascular ultrasound assessment of one saphenous vein graft as selected by randomization. The trial will be powered to test the hypothesis that clopidogrel and aspirin will reduce vein graft intimal hyperplasia by 20% compared to aspirin alone at one year following bypass surgery.</p><p><strong>Discussion: </strong>This trial is the first prospective human study that will address the question of whether clopidogrel therapy improves outcomes and reduces saphenous vein graft intimal hyperplasia following cardiac surgery. Should the combination of clopidogrel and aspirin reduce the process of vein graft intimal hyperplasia, the results of this study will help redefine modern antiplatelet management of coronary artery bypass patients.</p>","PeriodicalId":53230,"journal":{"name":"Current Controlled Trials in Cardiovascular Medicine","volume":"6 ","pages":"15"},"PeriodicalIF":0.0,"publicationDate":"2005-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1468-6708-6-15","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25651792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of post-operative mortality following treatment for non-ruptured abdominal aortic aneurysm.","authors":"Sigitas Urbonavicius,&nbsp;Henrik Vorum,&nbsp;Grazina Urbonaviciene,&nbsp;Mindaugas Trumpickas,&nbsp;Dainius Pavalkis,&nbsp;Bent Honoré","doi":"10.1186/1468-6708-6-14","DOIUrl":"https://doi.org/10.1186/1468-6708-6-14","url":null,"abstract":"<p><p>The aim of this prospective study of patients undergoing repair of non-ruptured abdominal aortic aneurysm between 1999 and 2003 was to evaluate and compare risk factors for mortality after surgery, to determine a complex of informative factors for lethal outcome, and to define patient risk groups. Logistic regression analysis revealed a complex of informative factors, including female gender, previous myocardial infarction, age greater than 75 years, and clinical course of abdominal aortic aneurysm as important indicators for lethal outcome. A risk score model identified low-, moderate- and high-risk groups with mortality rates of 2.9%, 8.0% and 44.4%, respectively.</p>","PeriodicalId":53230,"journal":{"name":"Current Controlled Trials in Cardiovascular Medicine","volume":"6 ","pages":"14"},"PeriodicalIF":0.0,"publicationDate":"2005-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1468-6708-6-14","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24996549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary artery bypass surgery in high-risk patients.","authors":"Alper Sami Kunt,&nbsp;Osman Tansel Darcin,&nbsp;Mehmet Halit Andac","doi":"10.1186/1468-6708-6-13","DOIUrl":"https://doi.org/10.1186/1468-6708-6-13","url":null,"abstract":"<p><strong>Background: </strong>In high-risk coronary artery bypass patients; off-pump versus on-pump surgical strategies still remain a matter of debate, regarding which method results in a lower incidence of perioperative mortality and morbidity. We describe our experience in the treatment of high-risk coronary artery patients and compare patients assigned to on-pump and off-pump surgery.</p><p><strong>Methods: </strong>From March 2002 to July 2004, 86 patients with EuroSCOREs > 5 underwent myocardial revascularization with or without cardiopulmonary bypass. Patients were assigned to off-pump surgery (40) or on-pump surgery (46) based on coronary anatomy coupled with the likelihood of achieving complete revascularization.</p><p><strong>Results: </strong>Those patients undergoing off-pump surgery had significantly poorer left ventricular function than those undergoing on-pump surgery (28.6 +/- 5.8% vs. 40.5 +/- 7.4%, respectively, p < 0.05) and also had higher Euroscore values (7.26 +/- 1.4 vs. 12.1 +/- 1.8, respectively, p < 0.05). Differences between the two groups were nonsignificant with regard to number of grafts per patient, mean duration of surgery, anesthesia and operating room time, length of stay intensive care unit (ICU) and rate of postoperative atrial fibrillation.</p><p><strong>Conclusion: </strong>Utilization of off-pump coronary artery bypass graft (CABG) does not confer significant clinical advantages in all high-risk patients. This review suggest that off-pump coronary revascularization may represent an alternative approach for treatment of patients with Euroscore > or = 10 and left ventricular function < or = 30%.</p>","PeriodicalId":53230,"journal":{"name":"Current Controlled Trials in Cardiovascular Medicine","volume":"6 ","pages":"13"},"PeriodicalIF":0.0,"publicationDate":"2005-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1468-6708-6-13","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25269184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction.","authors":"Aslan T Turer,&nbsp;Kenneth W Mahaffey,&nbsp;Dianne Gallup,&nbsp;W Douglas Weaver,&nbsp;Robert H Christenson,&nbsp;Nathan R Every,&nbsp;E Magnus Ohman","doi":"10.1186/1468-6708-6-12","DOIUrl":"https://doi.org/10.1186/1468-6708-6-12","url":null,"abstract":"<p><strong>Background: </strong>Cardiac biomarkers are routinely obtained in the setting of suspected myocardial ischemia and infarction. Evidence suggests these markers may correlate with functional and clinical outcomes, but the strength of this correlation is unclear. The relationship between enzyme measures of myocardial necrosis and left ventricular performance and adverse clinical outcomes were explored.</p><p><strong>Methods: </strong>Creatine kinase (CK) and CK-MB data were analyzed, as were left ventricular ejection fraction (LVEF) by angiogram, and infarct size by single-photon emission computed tomography (SPECT) imaging in patients in 2 trials: Prompt Reperfusion In Myocardial-infarction Evolution (PRIME), and Efegatran and Streptokinase to Canalize Arteries Like Accelerated Tissue plasminogen activator (ESCALAT). Both trials evaluated efegatran combined with thrombolysis for treating acute ST-segment elevation myocardial infarction (STEMI).</p><p><strong>Results: </strong>Peak CK and CK area-under-the-curve (AUC) correlated significantly with SPECT-determined infarct size 5 to 10 days after enrollment. Peak CK had a statistically significant correlation with LVEF, but CK-AUC and LVEF correlation were less robust. Statistically significant correlations exist between SPECT-determined infarct size and peak CK-MB and CK-MB AUC. However, there was no correlation with LVEF for peak CK-MB and CK-MB AUC. The combined outcome of congestive heart failure and death were significantly associated with CK AUC, CK-MB AUC, peak CK, and peak CK-MB measurements.</p><p><strong>Conclusion: </strong>Peak CK and CK-MB values and AUC calculations have significant correlation with functional outcomes (LVEF- and SPECT-determined infarct size) and death or CHF outcomes in the setting of STEMI. Cardiac biomarkers provide prognostic information and may serve as valid endpoint measurements for phase II clinical trials.</p>","PeriodicalId":53230,"journal":{"name":"Current Controlled Trials in Cardiovascular Medicine","volume":"6 ","pages":"12"},"PeriodicalIF":0.0,"publicationDate":"2005-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1468-6708-6-12","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25260458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The SPHERE Study. Secondary prevention of heart disease in general practice: protocol of a randomised controlled trial of tailored practice and patient care plans with parallel qualitative, economic and policy analyses. [ISRCTN24081411].","authors":"Andrew W Murphy,&nbsp;Margaret E Cupples,&nbsp;Susan M Smith,&nbsp;Molly Byrne,&nbsp;Claire Leathem,&nbsp;Mary C Byrne","doi":"10.1186/1468-6708-6-11","DOIUrl":"https://doi.org/10.1186/1468-6708-6-11","url":null,"abstract":"<p><strong>Background: </strong>The aim of the SPHERE study is to design, implement and evaluate tailored practice and personal care plans to improve the process of care and objective clinical outcomes for patients with established coronary heart disease (CHD) in general practice across two different health systems on the island of Ireland. CHD is a common cause of death and a significant cause of morbidity in Ireland. Secondary prevention has been recommended as a key strategy for reducing levels of CHD mortality and general practice has been highlighted as an ideal setting for secondary prevention initiatives. Current indications suggest that there is considerable room for improvement in the provision of secondary prevention for patients with established heart disease on the island of Ireland. The review literature recommends structured programmes with continued support and follow-up of patients; the provision of training, tailored to practice needs of access to evidence of effectiveness of secondary prevention; structured recall programmes that also take account of individual practice needs; and patient-centred consultations accompanied by attention to disease management guidelines.</p><p><strong>Methods: </strong>SPHERE is a cluster randomised controlled trial, with practice-level randomisation to intervention and control groups, recruiting 960 patients from 48 practices in three study centres (Belfast, Dublin and Galway). Primary outcomes are blood pressure, total cholesterol, physical and mental health status (SF-12) and hospital re-admissions. The intervention takes place over two years and data is collected at baseline, one-year and two-year follow-up. Data is obtained from medical charts, consultations with practitioners, and patient postal questionnaires. The SPHERE intervention involves the implementation of a structured systematic programme of care for patients with CHD attending general practice. It is a multi-faceted intervention that has been developed to respond to barriers and solutions to optimal secondary prevention identified in preliminary qualitative research with practitioners and patients. General practitioners and practice nurses attend training sessions in facilitating behaviour change and medication prescribing guidelines for secondary prevention of CHD. Patients are invited to attend regular four-monthly consultations over two years, during which targets and goals for secondary prevention are set and reviewed. The analysis will be strengthened by economic, policy and qualitative components.</p>","PeriodicalId":53230,"journal":{"name":"Current Controlled Trials in Cardiovascular Medicine","volume":"6 ","pages":"11"},"PeriodicalIF":0.0,"publicationDate":"2005-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1468-6708-6-11","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25220427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exercise training improves aerobic endurance and musculoskeletal fitness in female cardiac transplant recipients.","authors":"Mark Haykowsky, Kenneth Riess, Linda Figgures, Daniel Kim, Darren Warburton, Lee Jones, Wayne Tymchak","doi":"10.1186/1468-6708-6-10","DOIUrl":"10.1186/1468-6708-6-10","url":null,"abstract":"<p><strong>Aim: </strong>Female cardiac transplant recipients' aerobic capacity is 60% lower than sex and age-predicted values. The effect of exercise training on restoring the impaired aerobic endurance and muscle strength in female cardiac transplant recipients is not known. This study examined the effect that aerobic and strength training have on improving aerobic endurance and muscle strength in female cardiac transplant recipients.</p><p><strong>Methods: </strong>20 female cardiac transplant recipients (51 +/- 11 years) participated in this investigation. The subjects performed a baseline six-minute walk test and a leg-press strength test when they were discharged following cardiac transplantation. The subjects then participated in a 12-week exercise program consisting of aerobic and lower extremity strength training. Baseline assessments were repeated following completion of the exercise intervention.</p><p><strong>Results: </strong>At baseline, the cardiac transplant recipients' aerobic endurance was 50% lower than age-matched predicted values. The training program resulted in a significant increase in aerobic endurance (pre-training: 322 +/- 104 m vs. post-training: 501 +/- 99 m, p < 0.05) and leg-press strength (pre-training: 48 +/- 16 kg. vs. post-training: 78 +/- 27 kg, p < 0.05).</p><p><strong>Conclusion: </strong>Aerobic and strength training are effective interventions that can partially restore the impaired aerobic endurance and strength found in female cardiac transplant recipients.</p>","PeriodicalId":53230,"journal":{"name":"Current Controlled Trials in Cardiovascular Medicine","volume":" ","pages":"10"},"PeriodicalIF":0.0,"publicationDate":"2005-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1166569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40932533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study.","authors":"Bengt Fellström,&nbsp;Faiez Zannad,&nbsp;Roland Schmieder,&nbsp;Hallvard Holdaas,&nbsp;Alan Jardine,&nbsp;Helen Rose,&nbsp;Wim Wilpshaar","doi":"10.1186/1468-6708-6-9","DOIUrl":"https://doi.org/10.1186/1468-6708-6-9","url":null,"abstract":"<p><strong>Background: </strong>Patients with end-stage renal disease (ESRD) are at high risk of cardiovascular events. Multiple risk factors for atherosclerosis are present in ESRD and may contribute to the increased risk of cardiovascular mortality in this population. In contrast to patients with normal renal function, the benefits of modifying lipid levels on cardiovascular outcomes in patients with ESRD on haemodialysis have yet to be confirmed in large prospective randomised trials. A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events (AURORA) will be the first large-scale international trial to assess the effects of statin therapy on cardiovascular morbidity and mortality in ESRD patients on chronic haemodialysis.</p><p><strong>Methods: </strong>More than 2,750 ESRD patients who have been receiving chronic haemodialysis treatment for at least 3 months have been randomised (1:1), irrespective of baseline lipid levels, to treatment with rosuvastatin 10 mg or placebo. The primary study endpoint is the time to a major cardiovascular event (first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke). Secondary endpoints include all-cause mortality, major cardiovascular event-free survival time, time to cardiovascular death, time to non-cardiovascular death, cardiovascular interventions, tolerability of treatment and health economic costs per life-year saved. Study medication will be given until 620 subjects have experienced a major cardiovascular event.</p><p><strong>Conclusion: </strong>Our hypothesis is that results from AURORA will establish the clinical efficacy and tolerability of rosuvastatin in patients with ESRD receiving chronic haemodialysis and guide the optimal management of this expanding population.</p>","PeriodicalId":53230,"journal":{"name":"Current Controlled Trials in Cardiovascular Medicine","volume":" ","pages":"9"},"PeriodicalIF":0.0,"publicationDate":"2005-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1468-6708-6-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40925861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}